Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Boehringer Ingelheim Corporation Stories

2014-01-30 12:28:26

Unique academic-industry partnership will include an IPF patient registry and biomarker bank RIDGEFIELD, Conn. and DURHAM, N.C., Jan. 30, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Duke Clinical Research Institute (DCRI) have formed a unique collaborative relationship to uncover insights into idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. As part of the partnership, Boehringer Ingelheim and Duke Clinical Research Institute will...

2013-12-20 16:24:22

New Drug Application follows submission of Marketing Authorisation Application to the European Medicines Agency INDIANAPOLIS and RIDGEFIELD, Conn., Dec. 20, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for LY2963016, an investigational basal (long-acting) insulin. LY2963016 is a new insulin glargine product developed for the treatment of...

2013-12-17 08:28:51

RE-COVER II(TM) trial shows dabigatran non-inferior to warfarin in preventing recurrent DVT and/or PE and related death, with a reduction in major or clinically relevant non-major bleeding RIDGEFIELD, Conn., Dec. 17, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from the RE-COVER(TM) II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE). In this Phase III study,...

2013-12-11 08:32:30

GLENDALE, Calif. and RIDGEFIELD, Conn., Dec. 11, 2013 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed") (OTCQB: AMEH), an integrated physician-driven healthcare delivery company, and Boehringer Ingelheim Pharmaceuticals, Inc., a research-based, global pharmaceutical company, today announced a partnership dedicated to managing the care of ApolloMed ACO patients with chronic obstructive pulmonary disease (COPD). Boehringer Ingelheim has a vast array of provider and patient...

2013-12-02 12:25:54

More than 10,000 people with self-reported and diagnosed type 2 diabetes and more than 6,500 treating-physicians from 26 countries to take part in new survey RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 2, 2013 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the launch of the largest multinational survey to investigate early conversations between physicians and people living with type 2 diabetes at time of diagnosis and at time of treatment...

2013-11-19 08:28:10

New clinical trials of PRADAXA in different patient populations to add data to RE-VOLUTION®, BI's extensive clinical trial program RIDGEFIELD, Conn., Nov. 19, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. plans to initiate two new global clinical trials of PRADAXA. One of the new trials, RE-DUAL PCI(TM) ("Randomized Evaluation of Dual Therapy with Dabigatran vs. Triple Therapy Strategy with Warfarin in Patients with NVAF that have undergone PCI with Stenting"), is designed...

2013-11-18 12:30:28

New data include results for some PRADAXA patients studied for up to 6.7 years RIDGEFIELD, Conn., Nov. 18, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a new, long-term, combined analysis of the pivotal Phase III RE-LY® trial and its extension safety study RELY-ABLE®. The data showed that after a median follow up of 4.6 years, with some patients followed up to 6.7 years, rates of stroke/systemic embolism and major bleeding were consistent with...

2013-11-18 12:29:50

Data indicate the antidote may be able to achieve immediate, complete and sustained reversal of dabigatran-induced anticoagulation in healthy humans RIDGEFIELD, Conn., Nov. 18, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results showing that its investigational fully humanized antibody fragment (Fab) rapidly reversed the anticoagulation effect of dabigatran in healthy male volunteers. These results, presented today during the American Heart Association's...

2013-11-12 08:37:08

RIDGEFIELD, Conn., Nov. 12, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that data from eight company-sponsored PRADAXA studies will be presented at the American Heart Association's (AHA) Scientific Sessions in Dallas, November 16 to 20, 2013. The presentations - a mix of new clinical, epidemiological and pre-clinical data - will include long-term (median 4.6 years, maximum 6.7 years) follow-up data from the pivotal Phase III RE-LY® trial and its extension...

2013-11-07 08:32:37

Genetic biomarker testing at non-small cell lung cancer diagnosis helps inform a personalized treatment approach SAN CARLOS, Calif. and RIDGEFIELD, Conn., Nov. 7, 2013 /PRNewswire/ -- The Bonnie J. Addario Lung Cancer Foundation (ALCF) and Boehringer Ingelheim Pharmaceuticals, Inc. (BI) today announced that BI will sponsor ALCF's efforts to raise awareness about the importance of immediate genetic biomarker testing for patients with advanced non-small cell lung cancer (NSCLC). "This...